Drug intelligence / Profile preview

DIOS-301

Development stage: Preclinical
Lead developer: DiosCURE
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**DIOS-301** is a preclinical multivalent single-domain antibody nanobody candidate being developed by DiosCURE Therapeutics for prevention and treatment of COVID-19. It originated from a research collaboration led by the University of Bonn and is designed to bind multiple epitopes on the SARS-CoV-2 spike glycoprotein, neutralizing virions and aiming to reduce viral escape from emerging variants. DiosCURE described DIOS-301 and related candidates as multivalent single-chain nanobody constructs derived from camelid heavy-chain-only antibodies. ([businesswire.com](https://www.businesswire.com/news/home/20210728005061/en/DiosCURE-Announces-Exclusive-Worldwide-License-Agreement-for-Best-in-Class-Nanobodies-Against-COVID-19))

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on DIOS-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIOS-301.

Explore the full profile